Effect of Coffee and Agave Inulin-based Beverage on Appetite in Adults With Obesity.
Launched by UNIVERSITY OF GUADALAJARA · Jul 24, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
In Mexico, obesity has not ceased to increase since 1988, when it had a prevalence of only 9.5% compared to the 36.1% recorded in 2018, so it is necessary to start acting for the welfare of the Mexican population. In the search for a tool to complement nutritional intervention, we found coffee and inulin. Coffee consumption in our country increases 2% each year and according to data from PROFECO (Procuraduría Federal del Consumidor), 85% of Mexicans beverage one to three cups a day.
Agave tequilana Weber, a blue variety, is the most widely cultivated of the 117 species of agaves native to ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women
- • 25 to 55 years of age
- • BMI ≥ 30 and \<35 kg/m2
- • Habitual coffee consumption (1 - 3 cups of 240 ml of coffee per day)
- • Willingness to stop consuming food and/or supplements with coffee, caffeine and/or inulin during the study with the exception of the intervention
- • Availability of time in the mornings
- • Residents of the Guadalajara Metropolitan Area
- • Signed informed consent form
- Exclusion Criteria:
- • Hypersensitivity or intolerance to coffee or inulin
- • Allergy or intolerance to any of the test foods
- • Current or within the last 6 months use of weight-loss or appetite altering medications appetite altering medications
- • Diagnosis of diabetes, hypertension or any heart disease, thyroid disease, infectious disease (COVID-19, flu, etc.), digestive or inflammatory bowel disease or dysgeusia
- • Smoking
- • Women who are pregnant, want to become pregnant, or are breastfeeding
- • Peri-menopausal or menopausal women
- • Who are on any dietary regimen for weight loss
- • Currently or within the last 12 months participated in another study
- • Consumption of prebiotics or probiotics in the last three months
- • Incomplete data and/or measurements
- • Lack of expected compliance (drinking at least 5 of the 7 days of each week is considered compliance).
- • Individuals who decide to leave the study
About University Of Guadalajara
The University of Guadalajara, a prominent academic institution in Mexico, is dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a commitment to scientific excellence and ethical standards, the university collaborates with various stakeholders to conduct rigorous studies aimed at addressing critical health challenges. Its multidisciplinary approach harnesses the expertise of faculty and researchers across diverse fields, fostering a robust environment for the development of groundbreaking treatments and interventions. By actively contributing to the global body of medical knowledge, the University of Guadalajara plays a vital role in enhancing patient care and promoting public health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guadalajara, Jalisco, Mexico
Patients applied
Trial Officials
Livier N Torres, Ph.D
Study Director
University of Guadalajara
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported